Section Arrow
Quote
RIGL.NASDAQ
- Rigel Pharmaceuticals Inc
Quotes are at least 15-min delayed:2025/03/28 05:26 EDT
Last
 18.39
-0.59 (-3.11%)
Day High 
19.97 
Prev. Close
18.98 
1-M High
23.5 
Volume 
187.42K 
Bid
7.36
Ask
19.42
Day Low
18.35 
Open
19.51 
1-M Low
18.44 
Market Cap 
339.04M 
Currency USD 
P/E 19.17 
%Yield -- 
10-SMA 20.08 
20-SMA 20.5 
50-SMA 20.9 
52-W High 29.82 
52-W Low 7.4843 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.99/2.08
Enterprise Value
391.45M
Balance Sheet
Book Value Per Share
0.18
Cash Flow
Cash Flow Yield
0.09
Income Statement
Total Revenue
179.28M
Operating Revenue Per Share
7.41
Created with Highstock 5.0.121-min Chart10:0016:0012:0014:001818.51919.52020.5etnet.com.hk@copyright
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
OCEAOcean Biomedical0.078-0.0057-6.81%-- 
DRMADermata Therapeutics Inc.1.42+0.07+5.19%-- 
ONCOOnconetix Inc0.1077+0.0017+1.60%-- 
RGLSRegulus Therapeutics1.5+0.21+16.28%-- 
NKTXNkarta1.97+0.6+43.80%-- 
Quotes are at least 15-min delayed：2025/03/28 05:26 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.